Cabozantinib
- Generic Name
- Cabozantinib
- Brand Names
- Cabometyx, Cometriq
- Drug Type
- Small Molecule
- Chemical Formula
- C28H24FN3O5
- CAS Number
- 849217-68-1
- Unique Ingredient Identifier
- 1C39JW444G
- Background
Cabozantinib was first approved in 2012 and is a non-specific tyrosine kinase inhibitor. It was initially approved in the US under the brand name Cometriq, which is indicated for the treatment of metastatic medullary thyroid cancer. In 2016, a capsule formulation (Cabometyx) was approved for the treatment of advanced renal cell carcinoma, and this same formulation gained additional approval in both the US and Canada in 2019 for the treatment of hepatocellular carcinoma in previously treated patients.
- Indication
⑴治疗进展的、不能切除的局部晚期或转移的髓性甲状腺癌。
⑵用于舒尼替尼（索坦）治疗失败的晚期肾癌。
- Associated Conditions
- Advanced Renal Cell Carcinoma, Hepatocellular Carcinoma, Metastatic Differentiated Thyroid Cancer, Locally advanced Differentiated Thyroid Cancer (DTC), Metastatic Clear Cell Renal Cell Carcinoma (ccRCC), Progressive, metastatic Medullary thyroid cancer
- Associated Therapies
- -
Study to Assess the Pharmacokinetics of Cabozantinib (XL184) in Hepatic Impaired Adult Subjects
- First Posted Date
- 2011-12-16
- Last Posted Date
- 2014-09-22
- Lead Sponsor
- Exelixis
- Target Recruit Count
- 26
- Registration Number
- NCT01493869
- Locations
- 🇺🇸
McGuire VA Medical Center, Richmond, Virginia, United States
Cabozantinib in Advanced Pancreatic Neuroendocrine and Carcinoid Tumors
- Conditions
- Pancreatic Neuroendocrine TumorCarcinoid Tumor
- Interventions
- First Posted Date
- 2011-11-06
- Last Posted Date
- 2024-03-05
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 61
- Registration Number
- NCT01466036
- Locations
- 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
Cabozantinib in Women With Metastatic Hormone-Receptor-Positive Breast Cancer
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2011-09-28
- Last Posted Date
- 2023-01-10
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 68
- Registration Number
- NCT01441947
- Locations
- 🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
Trial of Cabozantinib (XL184) in Castrate-Resistant Prostate Cancer Metastatic to Bone
- First Posted Date
- 2011-09-02
- Last Posted Date
- 2017-12-12
- Lead Sponsor
- University of Michigan Rogel Cancer Center
- Target Recruit Count
- 25
- Registration Number
- NCT01428219
- Locations
- 🇺🇸
University of Michigan, Ann Arbor, Michigan, United States
Cabozantinib (XL184) in Men With Castrate-Resistant Prostate Cancer
- First Posted Date
- 2011-05-04
- Last Posted Date
- 2016-11-28
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 34
- Registration Number
- NCT01347788
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
A Drug-Drug Interaction Study of the Effects of XL184 (Cabozantinib) on Rosiglitazone in Subjects With Solid Tumors
- Conditions
- Papillary Thyroid CancerFollicular Thyroid CancerHuerthle Cell Thyroid CancerRenal Cell Carcinoma
- Interventions
- First Posted Date
- 2010-04-09
- Last Posted Date
- 2013-09-19
- Lead Sponsor
- Exelixis
- Target Recruit Count
- 40
- Registration Number
- NCT01100619
- Locations
- 🇺🇸
Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States
🇺🇸The University of Texas M.D. Anderson Cancer Center, Houston, Texas, United States
🇺🇸City of Hope Comprehensive Cancer Center, Duarte, California, United States
Study of Multiple Doses and Regimens of XL184 (Cabozantinib) in Subjects With Grade IV Astrocytic Tumors in First or Second Relapse
- First Posted Date
- 2010-02-15
- Last Posted Date
- 2014-07-30
- Lead Sponsor
- Exelixis
- Target Recruit Count
- 19
- Registration Number
- NCT01068782
Safety Study of XL184 (Cabozantinib) in Combination With Temozolomide and Radiation Therapy in the Initial Treatment of Adults With Glioblastoma
- Conditions
- GlioblastomaGliosarcomaGiant Cell Glioblastoma
- Interventions
- First Posted Date
- 2009-08-17
- Last Posted Date
- 2014-09-22
- Lead Sponsor
- Exelixis
- Target Recruit Count
- 26
- Registration Number
- NCT00960492
- Locations
- 🇺🇸
University of Virginia Health System/Division of Neuro-Oncology, Charlottesville, Virginia, United States
🇺🇸Duke University Medical Center; The Preston Robert Tisch Brain Tumor Center, Durham, North Carolina, United States
🇺🇸MD Anderson Cancer Center, Houston, Texas, United States
Study of Cabozantinib (XL184) in Adults With Advanced Malignancies
- First Posted Date
- 2009-07-15
- Last Posted Date
- 2024-04-25
- Lead Sponsor
- Exelixis
- Target Recruit Count
- 730
- Registration Number
- NCT00940225
- Locations
- 🇺🇸
Pinnacle Oncology of Arizona, Scottsdale, Arizona, United States
🇺🇸Cancer Centers of the Carolinas, ITOR, Greenville, South Carolina, United States
🇺🇸Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada, United States
Efficacy of XL184 (Cabozantinib) in Advanced Medullary Thyroid Cancer
- First Posted Date
- 2008-06-25
- Last Posted Date
- 2021-04-20
- Lead Sponsor
- Exelixis
- Target Recruit Count
- 330
- Registration Number
- NCT00704730
- Locations
- 🇺🇸
Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, Indiana, United States
🇺🇸Ohio State University, James Cancer Hospital, Columbus, Ohio, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.